Familial monoclonal gammopathy of undetermined significance and multiple myeloma: Epidemiology, risk factors, and biological characteristics

Blood

Volumn 119, Issue 23, 2012, Pages 5359-5366

  Greenberg, Alexandra J ^a   Rajkumar, S Vincent ^a   Vachon, Celine M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

B LYMPHOCYTE; BIOLOGICAL ACTIVITY; CELL AGGREGATION; DISEASE ASSOCIATION; ETHNICITY; FAMILIAL DISEASE; GENE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENETICS; GENOTYPE; HEMATOLOGIC MALIGNANCY; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MICROSATELLITE MARKER; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEROPREVALENCE; WALDENSTROEM MACROGLOBULINEMIA;

EID: 84862526485     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-387324     Document Type: Review

References (56)

1. Criteria for the classification of monoclonal gammopathies, multiple myeloma, and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-757.
2. Kyle R, Therneau T, Rajkumar S, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362-1639.
3. Iwanaga M, Tagawa M, Tsukasaki K, Kamihira S, Tomonaga M. Prevalence of monoclonal gammopathy of undetermined significance: study of 52802 persons in Nagasaki City, Japan. Mayo Clin Proc. 2007;82(12):1474-1479. (Pubitemid 350211694)
4. Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 2006;107(3):904-906. (Pubitemid 43156286)
5. Landgren O, Katzmann J, Hsing A, et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc. 2007;82(12):1468-1473. (Pubitemid 350211693)
6. Brown L, Linet M, Greenberg R, et al. Multiple myeloma and family history of cancer among blacks and whites in the US. Cancer. 1999;85(11):2385-2390. (Pubitemid 29244847)
7. Bourguet C, Grufferman S, Delzell E, DeLong E, Cohen H. Multiple myeloma and family history of cancer: a case-control study. Cancer. 1985;56(8):2133- 2139. (Pubitemid 15240897)
8. Landgren O, Kristinsson S, Goldin L, et al. Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood. 2009;114(4):791-795.
9. Vachon C, Kyle R, Therneau T, et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood. 2009;114(4):785-790.
10. Bizzaro N, Pasini P. Familial occurence of multiple myeloma and monoclonal gammopathy of undetermined significance in 5 siblings. Haematologica. 1990;75(1):58-63. (Pubitemid 20138538)
11. Steingrímsdóttir H, Einarsdóttir H, Haraldsdóttir V, Ogmundsdóttir H. Familial monoclonal gammopathy: hyper-responsive B cells in unaffected family members. Eur J Haematol. 2011;86(5):396-404.
12. Jain M, Ascensao J, Schechter G. Familial myeloma and monoclonal gammopathy: a report of eight African American families. Am J Hematol. 2009;84(1):34-38.
13. Lynch H, Ferrara K, Barlogie B, et al. Familial myeloma. N Engl J Med. 2008;359(2):152-157. (Pubitemid 351962038)
14. Kristinsson S, Bjorkholm M, Goldin L, et al. Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer. 2009;125(9):2147-2150.
15. Hemminki K, Li X, Czene K. Familial risk of cancer: data for clinical counseling and cancer genetics. Int J Cancer. 2004;108(1):109-114. (Pubitemid 37444452)
16. Grosbois B, Jego P, Attal M, et al. Familial multiple myeloma: report of fifteen families. Br J Haematol. 1999;105(3):768-770. (Pubitemid 29277038)
17. Eriksson M, Hallberg B. Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case-control study. Cancer Causes Control. 1992;3(1):63-67.
18. Kristinsson S, Bjorkholm M, Goldin L, McMaster M, Turesson I, Landgren O. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. Blood. 2008;112(8):3052-3056.
19. Lindqvist E, Goldin L, Landgren O, et al. Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood. 2011;118(24):6284-6291.
20. Kristinsson S, Goldin L, Bjorkholm M, Turesson I, Landgren O. Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance. Haematologica. 2009;94(8):1179-1181.
21. McMaster M, Goldin L, Bai Y, et al. Genomewide linkage screen for Waldenstrom macroglobulinemia susceptibility loci in high-risk families. Am J Hum Genet. 2006;79(4):695-701. (Pubitemid 44452746)
22. Grass S, Preuss K, Ahlgrimm M, et al. Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study. Lancet Oncol. 2009;10(10):950-956.
23. Grass S, Preuss K, Pfreundschuh M. Autosomal-dominant inheritance of hyperphosphorylated paratag-7. Lancet Oncol. 2010;11(1):12.
24. Grass S, Preuss K, Wikowicz A, et al. Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia. Blood. 2011;117(10):2918-2923.
25. Grass S, Preuss K, Thome S, et al. Paraproteins of familial MGUS/multiple myeloma target family-typical antigens: hyperphosphorylation of autoantigens is a consistent finding in familial and sporadic MGUS/MM. Blood. 2011;118(3):635-637.
26. Horwitz L, Levy R, Rosner F. Multiple myeloma in three siblings. Arch Intern Med. 1985;145(8):1449-1450. (Pubitemid 15049801)
27. Roddie P, Dang R, Parker A. Multiple myeloma in three siblings. Clin Lab Haematol. 1998;20(3):191-193. (Pubitemid 28313583)
28. Lynch H, Thome S. Familial multiple myeloma. Blood. 2009;114(4):749-750.
29. Lynch H, Watson P, Tarantolo S, et al. Phenotypic heterogeneity in multiple myeloma families. J Clin Oncol. 2005;23(4):685-693. (Pubitemid 46224167)
30. Gerkes E, Jong Md Sijmons R, Vellenga E. Familial multiple myeloma: report on two families and discussion of screening options. Hered Cancer Clin Pract. 2007;5(2):72-78. (Pubitemid 47067607)
31. Keshava-Prasad H, Prangnell D, Adelman M. Multiple myeloma in spouses. Clin Lab Haematol. 1996;18(1):61-62.
32. Lynch H, Sanger W, Pirruccello S, Quinn-Laquer B, Weisenburger D. Familial multiple myeloma: a family study and review of the literature. J Natl Cancer Inst. 2001;93(19):1479-1483. (Pubitemid 32982677)
33. Deshpande H, Hu X, Marino P, Jan N, Wiernik P. Anticipation in familial plasma cell dyscrasias. Br J Haematol. 1998;103(3):696-703. (Pubitemid 28545304)
34. Domingo-Domènech E, Benavente Y, Alvaro T, Hernández M, de Sevilla AF, de Sanjosé S. Family clustering of blood cancers as a risk factor for lymphoid neoplasms. Haematologica. 2005;90(3):416-418.
35. Ogmundsdóttir H, Haraldsdóttirm V, Jóhannesson G, et al. Familiality of benign and malignant paraproteinemias. A population-based cancer-registry study of multiple myeloma families. Haematologica. 2005;90(1):66-71.
36. Landgren O, Linet M, McMaster M, Gridley G, Hemminki K, Goldin L. Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study. Int J Cancer. 2006;118(12):3095-3098.
37. Goldin L, Pfeiffer R, Gridley G, et al. Familial aggregation of Hodgkin lymphoma and related tumors. Cancer. 2004;100(9):1902-1908. (Pubitemid 38529568)
38. McDuffie H, Pahwa P, Karunanayake C, Spinelli J, Dosman J. Clustering of cancer among families of cases with Hodgkin lymphoma (HL), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), soft tissue sarcoma (STS) and control subjects. BMC Cancer. 2009;9:70.
39. Camp N, Werner T, Cannon-Albright L. Familial myeloma. N Engl J Med. 2008;359(16):1734-1735.
40. Chapman M, Lawarence M, Keats J, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471(7339):467-472.
41. Hosgood H, Baris D, Zhang Y, et al. Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk. Leuk Res. 2009;33(12):1609-1614.
42. Lee K, Baris D, Zhang Y, et al. Common single nucleotide polymorphisms in immunoregulatory genes and multiple myeloma risk among women in Connecticut. Am J Hematol. 2010;85(8):560-563.
43. Kang S, Kim T, Kim H, et al. Protective role of CYP1A1*2A in the development of multiple myeloma. Acta Haematol. 2008;119(1):60-64. (Pubitemid 351363862)
44. Purdue M, Lan Q, Menashe I, et al. Variation in innate immunity genes and risk of multiple myeloma. Hematol Oncol. 2011;29(1):42-46.
45. Ostrovsky O, Korostishevsky M, Levite I, et al. Association of heparanase gene (HPSE) single nucleotide polymorphisms with hematological malignancies. Leukemia. 2007;21(11):2296-2303. (Pubitemid 350011702)
46. Abazis-Stamboulieh D, Oikonomou P, Papadoulis N, Panayiotidis P, Vrakidou E, Tsezou A. Association of interleukin-1A, interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms with multiple myeloma. Leuk Lymphoma. 2007;48(11):2196-2203. (Pubitemid 350091062)
47. Birmann B, Tamimi R, Giovannucci E, et al. Insulin-like growth factor-1-and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev. 2009;18(1):282-288.
48. Cooper P, McGuire B, Helfand B, Loeb S, Hu Q, Catalona W. Prostate cancer risk alleles and their associations with other malignancies. Urology. 2011;78(4):970.e915-970,e920.
49. Du J, Huo J, Shi J, et al. Polymorphisms of nuclear factor-kappaB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens. Haematologica. 2011;96(5):729-737.
50. Hayden P, Tewari P, Morris D, et al. Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma. Hum Mol Genet. 2007;16(24):3117- 3127.
51. Broderick P, Chubb D, Johnson D, et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat Genetics. 2011;44(1):58-61.
52. Skibola C, Bracci P, Halperin E, et al. Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. Nat Genet. 2009;41(8):873-875.
53. Slager S, Rabe K, Achenbach A, et al. Genomewide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood. 2011;117(6):1911-1916.
54. Conde L, Halperin E, Akers N, et al. Genomewide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet. 2010;42(8):661-664.
55. Crowther-Swanepoel D, Broderick P, Bernardo MD, et al. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet. 2010;42:132-136.
56. Smedby K, Foo J, Skibola C, et al. GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genetics. 2011;7(4):e1001378.